A phase 2 study of single agent ibrutinib for first-line treatment of chronic graft-versus-host disease: A new paradigm and lessons learned

El Jurdi N, Holtzman NG, Hishmeh R, Mina A, Schulz E, Stokes A, Li G, Schmidt KT, Figg WD, Micheletti N, Mays JW, Cowen EW, Pavletic SZ, Pusic I
У данной статьи нет абстракта.
British journal of haematology, 2025-05-07